Company: CERO
Filing Date: 2025-11-17
Form Type: PRE 14A
Source: 0001213900-25-111175
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-17
Form: PRE 14A
Chunk 3
---
 ADDITIONAL INFORMATION                                                                                            |     |   56 |
| APPENDIX A: CERTIFICATE OF AMENDMENT TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CERO THERAPEUTICS HOLDINGS, INC. |     |  A-1 |
| APPENDIX B: FOURTH AMENDMENT TO THE CERO THERAPEUTICS HOLDINGS, INC. 2024 EQUITY INCENTIVE PLAN                                      |     |  B-1 |

i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This proxy statement (this “proxy statement”) contains forward -lookingstatements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this proxy statement, including statements regarding the Company’s future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical studies, clinical trials, research and development (“R&D”) costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward -lookingstatements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company’s control and may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward -lookingstatements. In some cases, you can identify forward -lookingstatements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential,” or “continue” or the negative of these terms or other similar expressions. Forward -lookingstatements contained in this proxy statement include, but are not limited to, statements about: •our financial performance; •our ability to obtain additional cash and the sufficiency of our existing cash, cash equivalents and equity securities to fund our future operating expenses and capital expenditure requirements, including the development and, if approved, commercialization of our product candidates; •the impact of the delisting of our Common Stock and public warrants from the NASDAQ Stock Market (“Nasdaq”); •our ability to realize the benefits expected from the business combination (